Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
FBL7 Double Nickase Plasmid (h): sc-405043-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FBL7 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- FBL7 Double Nickase Plasmid (h) and FBL7 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting FBXL7. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FBL7 Antibody (A-8): sc-374319
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FBL7 Double Nickase Plasmid (h) | sc-405043-NIC | 20 µg | $410.00 | |||
FBL7 Double Nickase Plasmid (h2) | sc-405043-NIC-2 | 20 µg | $410.00 |
FBXL7 (FBL7) encodes an F-box protein that is predicted to serve as a substrate-recognition component of SCF (SKP1–CUL1–F-box) E3 ubiquitin ligase complexes, helping direct selected proteins toward ubiquitination and proteasomal turnover. Through this role, FBXL7 is linked to core proteostasis mechanisms that shape cell-cycle progression, stress responses, and signal transduction by controlling the stability of pathway regulators. Perturbation of ubiquitin–proteasome system components and F-box adaptors is frequently associated with dysregulated growth and altered apoptotic thresholds, making FBXL7 a gene of interest in mechanistic cancer biology and related signaling studies. Expression and genomic alterations in FBXL7 have been reported across tumor datasets, supporting its relevance for investigating how ubiquitin-mediated protein control influences disease-associated cellular phenotypes.
FBL7 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the FBXL7 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within FBXL7. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt FBXL7 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of FBXL7-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.